Data Sheet 1_Assessment of real-world surveillance strategies for patients undergoing syst

A single-institution retrospective study of 33 patients treated with systemic therapy alone for active brain metastases from 2021 to 2024. Britney Weng authored this research, which assesses MRI surveillance timing, intracranial progression, survival, and adverse events. The dataset was last updated on April 20, 2026.

Use Cases

• Compare surveillance MRI timing intervals based on the reported median days to 1st, 2nd, and 3rd scans.
• Analyze the cumulative incidence of local progression and brain radiation based on patient stratification by treatment guidelines.
• Assess the safety profile of CNS-penetrating systemic therapies based on the reported neurological adverse events.

Strengths

• Includes data from 33 patient records, providing a clinical cohort for analysis.
• Reports specific median time intervals for surveillance MRIs: 45, 95, and 180 days.
• Provides one-year cumulative incidence rates with 95% confidence intervals for key outcomes.
• Stratifies patients by adherence to the 2021 ASCO-SNO-ASTRO guidelines, enabling comparative analysis.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single institution, which may limit generalizability.

Provenance

Source

figshare

Collection Method

Retrospective review of patient records at a single institution.

Time Range

2021-2024

Freshness

Last updated 2026-04-20 04:13:11; freshness should be verified.

Geography

Single institution; specific location not stated.